Cart
sales@molnova.com
Adrafinil
CAS No. 63547-13-7
Adrafinil( benzhydrylsulfinylacetohydroxamic acid | adrafinyl | CRL-40028 )
Catalog No. M20900 CAS No. 63547-13-7
Adrafinil?is used to relieve excessive sleepiness and inattention in elderly patients.?
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAdrafinil
-
NoteResearch use only, not for human use.
-
Brief DescriptionAdrafinil?is used to relieve excessive sleepiness and inattention in elderly patients.?
-
DescriptionAdrafinil?is used to relieve excessive sleepiness and inattention in elderly patients.?
-
In Vitro——
-
In Vivo——
-
Synonymsbenzhydrylsulfinylacetohydroxamic acid | adrafinyl | CRL-40028
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number63547-13-7
-
Formula Weight289.35
-
Molecular FormulaC15H15NO3S
-
Purity>98% (HPLC)
-
SolubilityDMSO:57mg/mL(196.99mM)
-
SMILESO=C(CS(=O)C(c1ccccc1)c1ccccc1)NO
-
Chemical Name2-((Diphenylmethyl)sulfinyl)-N-hydroxyacetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Michel B Roger B . Modafinil: its discovery the early European and North American experience in the treatment of narcolepsy and idiopathic hypersomnia and its subsequent use in other medical conditions[J]. Sleep Medicine 2018:S1389945718302211-.
molnova catalog
related products
-
PS-47
PS-47 is an inactive E-isomer of PS48. PS48 is an activator of PDK1.
-
Patulitrin
Patulitrin has antioxidant, anti-inflammatory, and larvicidal activities, oral and topical administration of patuletin and patulitrin inhibited acute inflammation in mice.
-
25-Hydroxycholestero...
25-Hydroxycholesterol is a steroid derivative that suppresses the cleavage of sterol regulatory element binding proteins (SREBPs).
